{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:30:40Z","timestamp":1736400640200,"version":"3.32.0"},"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>People with immunocompromising conditions (IC) are at increased risk of severe COVID-19 and death. These individuals show weaker immunogenicity following vaccination than individuals without IC, yet immunogenicity after SARS-CoV-2 infection is poorly understood. To address this gap, the presence of infection-induced antibodies in sera following a positive COVID-19 test result was compared between patients with and without IC. A commercial laboratory provided patient data gathered during July 2020\u2013February 2022 on COVID-19 viral test results and antibody assay results, which included infection-induced (anti-N) antibody presence. Participants were categorized into having or not having IC based on if there was an indicative diagnostic code on their health record for a five-year period prior to the study period. Anti-N presence in sera from people with a positive COVID-19 test result was compared by IC status for four post-infection periods: 14\u201390, 91\u2013180, 181\u2013365, and 365+ days. A longitudinal, logistic regression produced adjusted odds ratios comparing anti-N prevalence among specimens with and without associated IC, adjusted for age, sex, residence in a metro area, and social vulnerability index (SVI) tertile. Data included 17,025 anti-N test results from 14,690 patients, 1,424 (9.7%) of which had at least one IC on record. In an adjusted comparison to patients without IC, patients with any IC were 0.61 times as likely to have infection-induced antibodies (99% CI: 0.40\u20130.93), during the 14\u201390 days following infection. Similar patterns were found when comparing people with two specific types of IC to people without any IC: (1) solid malignancies and (2) other intrinsic immune conditions. These findings stress the importance of prevention measures for people with IC, such as additional vaccination doses and consistent mask use before and after a documented infection.<\/jats:p>","DOI":"10.1371\/journal.pone.0313620","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:24:38Z","timestamp":1736364278000},"page":"e0313620","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions\u2014United States, 2020\u20132022"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-1249","authenticated-orcid":true,"given":"Anna","family":"Bratcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-9058","authenticated-orcid":true,"given":"Jefferson M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehan","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Yazgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi V.","family":"Gundlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristie E. N.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"7821","key":"pone.0313620.ref001","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"EJ Williamson","year":"2020","journal-title":"Nature"},{"key":"pone.0313620.ref002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103355","article-title":"Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series.","volume":"67","author":"TT Truong","year":"2021","journal-title":"EBioMedicine"},{"key":"pone.0313620.ref003","author":"SE Oliver","year":"2021","journal-title":"Data and clinical considerations for additional doses in immunocompromised people"},{"issue":"4","key":"pone.0313620.ref004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14760584.2022.2035222","article-title":"COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies","volume":"21","author":"M Di Fusco","year":"2022","journal-title":"Expert Review of Vaccines"},{"key":"pone.0313620.ref005","author":"Wong SY Lee ARYB","year":"2021","journal-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis"},{"issue":"3","key":"pone.0313620.ref006","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","article-title":"Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review","volume":"10","author":"EP Parker","year":"2022","journal-title":"The Lancet Global Health"},{"issue":"44","key":"pone.0313620.ref007","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","article-title":"Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19\u2013associated hospitalizations among immunocompromised adults\u2014nine states, January\u2013September 2021","volume":"70","author":"PJ Embi","year":"2021","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"9","key":"pone.0313620.ref008","doi-asserted-by":"crossref","first-page":"1256. e9","DOI":"10.1016\/j.cmi.2020.05.036","article-title":"Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection","volume":"26","author":"K Chew","year":"2020","journal-title":"Clinical Microbiology and Infection"},{"key":"pone.0313620.ref009","volume-title":"USDA economic research service","author":"R-UC Codes","year":"2014"},{"issue":"1","key":"pone.0313620.ref010","doi-asserted-by":"crossref","first-page":"0000102202154773551792","DOI":"10.2202\/1547-7355.1792","article-title":"A social vulnerability index for disaster management","volume":"8","author":"BE Flanagan","year":"2011","journal-title":"Journal of homeland security and emergency management"},{"issue":"4","key":"pone.0313620.ref011","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/M21-3272","article-title":"What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection? Rapid, living practice points from the american college of physicians (Version 2).","volume":"175","author":"A Qaseem","year":"2022","journal-title":"Annals of Internal Medicine"},{"key":"pone.0313620.ref012","author":"CDC","year":"2023","journal-title":"People Who Are Immunocompromised: Know how to protect yourself and what to do if you get sick"},{"key":"pone.0313620.ref013","doi-asserted-by":"crossref","first-page":"109097","DOI":"10.1016\/j.clim.2022.109097","article-title":"COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review","author":"E Drzymalla","year":"2022","journal-title":"Clinical Immunology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:24:48Z","timestamp":1736364288000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313620"}},"subtitle":[],"editor":[{"given":"Timothy J.","family":"Wade","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313620","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}